4SC AG EV/EBITDA
¿Qué es el EV/EBITDA de 4SC AG?
El EV/EBITDA de 4SC AG es 0.60
¿Cuál es la definición de EV/EBITDA?
EV / EBITDA es el valor de la empresa dividido por las ganancias antes de intereses, impuestos, depreciación y amortización. Es una medida de cuál cara es una acción y es más frecuentemente válida para comparaciones entre compañías que la relación precio / ganancias. Mide el precio (en forma de valor empresarial) que un inversionista paga en beneficio del flujo de caja de la compañía (en forma de EBITDA).
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV/EBITDA de compañías en Sector Health Care en XETRA en comparadas con 4SC AG
¿Qué hace 4SC AG?
4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company's products in clinical development stage include Resminostat, an orally administered histone deacetylase inhibitor that is in Phase II clinical trial for the treatment of cutaneous T-cell lymphoma; and Domatinostat, an orally administered small molecule, which is in Phase Ib/II clinical trial for the treatment of melanoma and Phase II clinical trial for the treatment of gastrointestinal tumor. 4SC AG also out-licenses its products to pharma and biotech companies for the treatment of cancer. The company has a collaboration agreement with the Netherlands Cancer Institute to evaluate Domatinostat in the neoadjuvant setting in melanoma. 4SC AG was founded in 1997 and is headquartered in Planegg, Germany.
Empresas con ev/ebitda similar a 4SC AG
- Satsuma Pharmaceuticals tiene EV/EBITDA de 0.59
- QPL International tiene EV/EBITDA de 0.59
- Cobra Venture tiene EV/EBITDA de 0.59
- Unico American tiene EV/EBITDA de 0.59
- Questerre tiene EV/EBITDA de 0.60
- AHAlife tiene EV/EBITDA de 0.60
- 4SC AG tiene EV/EBITDA de 0.60
- Guangnan () tiene EV/EBITDA de 0.61
- Enveric Biosciences tiene EV/EBITDA de 0.61
- FibroGen Inc tiene EV/EBITDA de 0.61
- Silverback Therapeutics tiene EV/EBITDA de 0.61
- Billing Services tiene EV/EBITDA de 0.61
- STM Plc tiene EV/EBITDA de 0.61